- Home
- RFAM vs BDSX Comparison
RFAM vs BDSX Comparison
Compare RFAM & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFAM | BDSX |
|---|---|---|
| Founded | 2025 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.1M | 162.8M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RFAM | BDSX |
|---|---|---|
| Price | $9.86 | $14.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 13.8K | ★ 76.0K |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $9.77 | $0.25 |
| 52 Week High | $9.94 | $20.21 |
Technical Indicators
Market Signals| Indicator | RFAM | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 55.52 |
| Support Level | $9.81 | $12.77 |
| Resistance Level | $9.90 | $16.26 |
| Average True Range (ATR) | 0.00 | 1.16 |
| MACD | 0.00 | 0.53 |
| Stochastic Oscillator | 50.00 | 72.20 |
Price Performance
Historical ComparisonAbout RFAM RF Acquisition Corp III Ordinary Shares
RF Acquisition Corp III is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.